A biotech startup from the University of Manchester, Imperagen, has successfully secured £5 million in seed funding led by PXN Ventures, aimed at advancing its innovative work in AI and quantum physics for enzyme engineering.
This funding round, which also includes contributions from existing investors IQ Capital and Northern Gritstone, brings Imperagen's total funding to £8.5 million. The capital will be utilized to expand research and development, enhance laboratory operations, and grow the AI team over the next 18 months. Guy Levy-Yurista has been appointed as CEO to spearhead this growth, emphasizing the company’s unique technological edge and its "Manchester swagger."
Founded in 2021 by a team of researchers from the Manchester Institute of Biotechnology, Imperagen focuses on creating enzymes for various applications, including pharmaceuticals and personal care. The company employs a unique three-stage closed-loop process that integrates quantum physics and AI to optimize enzyme development, significantly increasing productivity compared to traditional methods.
The latest funding will allow Imperagen to scale its operations and enhance its marketing efforts, targeting key sectors such as pharmaceuticals and sustainable fine chemicals. As the life sciences ecosystem in the North West continues to strengthen, Imperagen's innovative approach positions it well for future successes in enzyme engineering and broader applications within the industry.